SPRINT Results Transportable to CKD Patients From Clinical Practice
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 9, 2025 -- The outcomes of intensive versus standard blood pressure (BP) control seen in the Systolic Blood Pressure Intervention Trial (SPRINT) are transportable to trial-eligible chronic kidney disease (CKD) patients from clinical practice, according to a study published online Jan. 7 in JAMA Network Open.
Manjula Kurella Tamura, M.D., M.P.H., from Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a comparative effectiveness study to examine whether the beneficial and adverse effects of intensive versus standard BP control seen in SPRINT are transportable to two populations with CKD who met eligibility criteria for SPRINT from the Veterans Health Administration (VHA; 85,938 patients) and Kaiser Permanente of Southern California (KPSC; 13,983 patients).
The researchers found that patients from the VHA and KPSC were older, had less prevalent cardiovascular disease, higher albuminuria, and used more statins compared with the 9,361 SPRINT participants. The associations of intensive versus standard BP control with major cardiovascular events, all-cause death, and adverse events were transportable to the VHA and KPSC populations; in one or both populations, the trial's effect on cognitive and CKD outcomes was not transportable. Intensive versus standard BP treatment was associated with lower absolute risks for major cardiovascular events at four years by 5.1 and 3.0 percent in the VHA and KPSC populations, respectively, and with higher risks for adverse events by 1.3 and 3.1 percent in the VHA and KPSC populations, respectively.
"We found that the trial results were transportable to the clinical populations and corresponded with similar or more favorable benefits on the absolute scale," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
MONDAY, July 21, 2025 -- For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved...
ENDO: Primary Aldosteronism Screening Recommended for All With Hypertension
FRIDAY, July 18, 2025 -- All individuals with hypertension should be screened for primary aldosteronism (PA), according to a clinical practice guideline issued by the Endocrine...
Delays in HTN Diagnosis Linked to Delays in Medication Prescribing
THURSDAY, July 17, 2025 -- Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.